Wellcome Trust Sanger Institute Adopts DNASTAR Lasergene Software
News Dec 05, 2013
DNASTAR has announced that the Wellcome Trust Sanger Institute entered into a multi-year software license agreement with DNASTAR for the use of Lasergene software as its primary sequence assembly and analysis software platform for researchers within its organization.
A spokesperson for the Wellcome Trust Sanger Institute said, “The Sanger Institute is one of the world’s leading genomics organizations and we have a real need for sequence analysis software that performs. Our researchers need access to a common set of tools that help them to share data: that is part of our Institute ethos. The solution for our analysis must be flexible and able to respond to changing demands.”
Tom Schwei, Vice President and General Manager of DNASTAR, stated, “We are delighted to have entered into this agreement with the Wellcome Trust Sanger Institute, a recognized global leader in genomic research. This site license will support scientists and staff at the Sanger Institute in all of their scientific research endeavors for many years to come. As we continue to develop our software, all scientists within the Institute will benefit by having immediate access to the most recent innovations in our products. We appreciate the trust placed in our software, support, and company by the Sanger Institute and we look forward to continuing to meet their sequence assembly and analysis software needs in the future.”
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.